NGM · Biotechnology

Jyong Biotech Ltd. (MENS) Stock

$2.05 -2.38% NGM: MENS Healthcare

Valuation

MetricValue
Price$2.05
Market Cap$155.86M
P/E Ratio-23.82
P/B Ratio-6.14
P/S Ratio0.00
EPS (TTM)$-0.04
52-Week High$63.00
52-Week Low$1.43
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE19.39%
ROA-22.49%
ROCE18.59%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity-0.74
Current Ratio0.62

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-2.0M$-3.0M$-3.0M$-2.0M$-3.0M
Net Profit$-4.0M$-7.0M$-4.0M$-3.0M$-5.0M
EPS$-0.06$-0.09$-0.06$-0.04$-0.06
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$9.0M$9.0M$8.0M$6.0M$21.0M
Total Liabilities$33.0M$38.0M$42.0M$43.0M$46.0M
Cash$1.0M$1.0M$0$0$1.0M
Borrowings$12.0M$14.0M$17.0M$18.0M$19.0M

Latest News

Jyong Biotech Showcases Botanical Drug Portfolio at BIO 2026 International Convention PR Newswire · Jul 3, 2026 Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview PR Newswire · Jun 1, 2026 Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025 GlobeNewswire · May 15, 2026 Jyong Biotech Updates Market Access Strategy for Innovative Botanical Drugs, Establishing Multiple Competitive Advantages for New Drug Portfolio PR Newswire · Apr 29, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-2.0M$-3.0M$-3.0M$-4.0M$-3.0M
Investing Cash Flow$-1.0M$1.0M$0$0$-14.0M
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$-5.0M$2.0M$-1.0M$-2.0M$1.0M
Free Cash Flow$-2.0M$-3.0M$-3.0M$-4.0M$-3.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.49
EV / EBITDA-66.23
FCF Yield0.00%
Quick Ratio0.45
Interest Coverage-1.03
Return 1Y-75.70%
Return 3Y—
Return 5Y—

Ownership

Insiders Held62.20%
Institutions Held0.71%
Institutions Float Held1.89%
Institutional HolderSharesReport Date
Blackrock Inc.258,7602026-03-31
Geode Capital Management, LLC64,2322026-03-31
UBS Group AG37,3632026-03-31
China Universal Asset Management Co., Ltd.13,1732026-03-31
Vanguard Personalized Indexing Management, LLC13,9272026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPGAscentage Pharma Group International $20.18 +4.89% -9.87 $1.88B 0.00%
APGE $135.07 +0.00% -16.89 $8.36B 0.00%
CELCCelcuity Inc. $67.94 +0.10% -16.81 $3.31B 0.00%
CGONCG Oncology, Inc. $63.82 +0.89% -26.26 $5.63B 0.00%
CNTACentessa Pharmaceuticals plc $40.50 +0.00% -22.75 $6.27B 0.00%

About Jyong Biotech Ltd.

Jyong Biotech Ltd. is led by CEO Fu-Feng Kuo, employs 31 people, headquartered in TW, publicly traded since 2025.

Jyong Biotech Ltd. (MENS) stock trades at $2.05 with a market capitalization of $155.86M. The stock is valued at a price-to-earnings (P/E) ratio of -23.82, price-to-book of -6.14, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.43 and $63.00, and currently trades 96.7% below its 52-week high.

On profitability, Jyong Biotech Ltd. generates a return on equity (ROE) of 19.39%, above the typical market average, return on capital employed of 18.59%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.31 +0.33% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.67 +1.27%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides